Avelumab has been filed for use in patients ... Merck Inc and Pfizer had seemed like outsiders in the immunotherapy race just two years ago, when PD-1 inhibitors Merck’s Keytruda and BMS ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

A novel immunotherapy approach developed by Ludwig ... combining these CV1-producing T cells with cancer-targeting antibodies such as avelumab and cetuximab further improved the ability of ...

Dr. Daniel P. Petrylak discusses the different types of bladder cancer and how treatment options may vary based on disease ...

An evaluation of nearly 19,000 patients with metastatic colorectal cancer supported clinical trial data that immunotherapy ...

Instead, she received just one treatment — immunotherapy — as part of a clinical trial at Memorial Sloan Kettering. It’s been two years since she completed her treatment and she’s in ...

PT-112—a platinum-containing immunotherapy agent Phosplatin is ... Pfizer and Merck KGaA on a combination study of PT-112 and avelumab in solid tumors, and a sub-licensing agreement for Greater ...

Immunotherapy works by interfering with this ... Common immune checkpoint inhibitors are programmed death-ligand 1 inhibitors (e.g. avelumab), programmed cell death protein 1 inhibitors (e.g ...

Nghiem was also the senior author on the Lancet Oncology article that preceded the approval. He is a leading expert on MCC and a pioneer of immunotherapy for the disease.

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical ... precision medicine with a novel immunotherapy that is fully tailored ...